Gamechangers
We address public health needs by developing a self-amplifying RNA-based platform for rapid and scalable manufacturing of innovative medical tools.
Our Technology
Lipid nanoparticle
(LNP)
The in-house developed LNP library at Ziphius is specifically designed for saRNA delivery, ensuring proper encapsulation, stability, and biodegradability of the LNP-saRNA complex. Ziphius is also focused on developing LNPs for various administration routes across a range of therapeutic applications. The platform is being optimized to achieve optimal efficacy in infectious disease vaccines, therapies for rare diseases and oncology.
Self-amplifying RNA
(saRNA)
Over conventional RNA, saRNA has the unique ability to replicate itself, thereby amplifying the number of coding sequences from a single molecule. SaRNAs are thus expected to induce higher amounts of the protein of interest at a much lower dosage and for a longer duration. For vaccines, this can translate into longer protection than the conventional RNA vaccines along with enhanced immune memory. In the case of rare diseases, saRNA could bring a long-term expression of the deficient or replacement protein, offering a new therapeutic modality with a convenient administration schedule. In oncology, saRNA offers diverse applications, ranging from personalised cancer vaccines to the expression of chimeric antigen receptors (CARs) on immune cells for use in immunotherapy.
Pipeline
Ziphius aims to leverage the use of its self-amplifying RNA platform to develop innovative solutions across a range of applications, from infectious disease prevention to advanced therapies for rare diseases and next-generation oncology treatments.
Join our team
Ziphius’ team consists of a well-balanced group of people with complementary skills and a background ranging from biology, virology, chemistry till pharmaceutical sciences. The team members are united by their common passion for science, health care, innovation and entrepreneurship.
Ziphius Announces Appointment of Damien Dessis as Chief Business Officer (CBO)
Ziphius, a leading biotechnology company developing self-amplifying RNA (saRNA) vaccines and therapeutics, today announced the appointment of Damien Dessis as Chief Business Officer. In this role, Mr. Dessis will be responsible for overseeing the Company’s business development and overall corporate strategy.